Thrombosis and Bleeding in Cancer Patients

  • Wolfgang Korte


Cancer patients are known to exhibit a hypercoagulable state with a high risk for thrombosis and pulmonary embolism. Recent data suggest that thromboprophylaxis in cancer patients is likely to be underused. This is important as there is some evidence that the use of low molecular weight heparin (LMWH) improves the response to chemotherapy and is also likely to be able to improve survival. In the palliative care setting, patients seem willing to accept the use of subcutaneous LMWH injections as compared to compression stockings because of the greater efficacy.

Research has also shown that the provident, structured use of blood products in patients undergoing chemotherapy reduces the need for them and therefore potential side effects to the patients. This also leads to reduced resource consumption and thus reduced economic strain on the healthcare system. Bleeding complications in cancer patients undergoing surgery are not infrequent and have recently been linked to reduced crosslinking capacity. Novel strategies for perioperative risk stratification in cancer patients have been developed. More clinical research is needed to improve our understanding of thrombosis and bleeding in cancer patients.


Acute Myelogenous Leukemia Polycythemia Vera Coagulation Activation Compression Stocking Portal Vein Tumor Thrombus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Virchow R. Phlogose und Thrombose in Geaszsystem. In: Virchow R, ed. Gesammelte abhandlungen zur Wissenschafilichem Medicin Frankfurt von Meidinger Soln. 1856:458–636.Google Scholar
  2. 2.
    Trousseau A. Phlegmasia alba dolens. Clinique medicale de l’Hotel-Dien de Paris. 1865. Paris: The Sydenham Society.Google Scholar
  3. 3.
    Schaffner F, Ruf W. Tissue factor and PAR2 signaling in the tumor microenvironment. Arterioscler Thromb Vasc Biol. 2009;29(12):1999–2004.PubMedCrossRefGoogle Scholar
  4. 4.
    Korte W. Changes of the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures. Clin Chem Lab Med. 2000;38(8):679–92.PubMedCrossRefGoogle Scholar
  5. 5.
    Beer JH, Haeberli A, Vogt A, Woodtli K, Henkel E, Furrer T, et al. Coagulation markers predict survival in cancer patients. Thromb Haemost. 2002;88(5):745–9.PubMedGoogle Scholar
  6. 6.
    Antoniou D, Pavlakou G, Stathopoulos GP, Karydis I, Chondrou E, Papageorgiou C, et al. Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer. Lung Cancer. 2006;53(2):205–10.PubMedCrossRefGoogle Scholar
  7. 7.
    Wada H, Mori Y, Okabayashi K, Gabazza EC, Kushiya F, Watanabe M, et al. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients. Am J Hematol. 2003;72(1):1–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta Haematol. 2001;106(1–2):6–12.PubMedCrossRefGoogle Scholar
  9. 9.
    White RH, Chew HK, Zhou H, Parikh-Patel A, Harris D, Harvey D, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med. 2005;165(15):1782–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Murchison JT, Wylie L, Stockton DL. Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study. Br J Cancer. 2004;91(1):92–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715–22.PubMedCrossRefGoogle Scholar
  12. 12.
    Jimenez-Zepeda VH, Dominguez-Martinez VJ. Acquired activated protein C resistance and thrombosis in multiple myeloma patients. Thromb J. 2006;4:11.PubMedCrossRefGoogle Scholar
  13. 13.
    Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006;24(3):484–90.PubMedCrossRefGoogle Scholar
  14. 14.
    Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339–46.PubMedCrossRefGoogle Scholar
  15. 15.
    Otten HM, Mathijssen J, ten Cate H, Soesan M, Inghels M, Richel DJ, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med. 2004;164(2):190–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Chew HK, Wun T, Harvey DJ, Zhou H, White RH. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol. 2007;25(1):70–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Linenberger ML, Wittkowsky AK. Thromboembolic complications of malignancy. Part 1: risks. Oncology (Williston Park, NY). 2005;19(7):853–61.Google Scholar
  18. 18.
    von Tempelhoff GF, Heilmann L, Hommel G, Schneider D, Niemann F, Zoller H. Hyperviscosity syndrome in patients with ovarian carcinoma. Cancer. 1998;82(6):1104–11.CrossRefGoogle Scholar
  19. 19.
    Sharma K, Puniyani RR, Bhat SV, Advani SH, Hegde U, Rao S. Blood viscosity parameter correlation with types of leukemia. Physiol Chem Phys Med NMR. 1992;24(2):159–64.PubMedGoogle Scholar
  20. 20.
    Finazzi G. A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). Pathol Biol. 2004;52(5):285–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Landolfi R, Ciabattoni G, Patrignani P, Castellana MA, Pogliani E, Bizzi B, et al. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood. 1992;80(8):1965–71.PubMedGoogle Scholar
  22. 22.
    De Stefano V, Za T, Rossi E, Fiorini A, Ciminello A, Luzzi C, et al. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. Haematologica. 2009;94(5):733–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Ventura GJ, Hester JP, Smith TL, Keating MJ. Acute myeloblastic leukemia with hyperleukocytosis: risk factors for early mortality in induction. Am J Hematol. 1988;27(1):34–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005;104(12):2822–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Otten TR, Stein PD, Patel KC, Mustafa S, Silbergleit A. Thromboembolic disease involving the superior vena cava and brachiocephalic veins. Chest. 2003;123(3):809–12.PubMedCrossRefGoogle Scholar
  26. 26.
    Hiraiwa K, Morozumi K, Miyazaki H, Sotome K, Furukawa A, Nakamaru M, et al. Isolated splenic vein thrombosis secondary to splenic metastasis: a case report. World J Gastroenterol. 2006;12(40):6561–3.PubMedGoogle Scholar
  27. 27.
    Bergqvist D. Venous thromboembolism: a review of risk and ­prevention in colorectal surgery patients. Dis Colon Rectum. 2006;49(10):1620–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Le Treut YP, Hardwigsen J, Ananian P, Saisse J, Gregoire E, Richa H, et al. Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature. A European case-control series. J Gastrointest Surg. 2006;10(6):855–62.PubMedCrossRefGoogle Scholar
  29. 29.
    Chen XP, Qiu FZ, Wu ZD, Zhang ZW, Huang ZY, Chen YF, et al. Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma. Ann Surg Oncol. 2006;13:940–46.PubMedCrossRefGoogle Scholar
  30. 30.
    Sakuma M, Fukui S, Nakamura M, Takahashi T, Kitamukai O, Yazu T, et al. Cancer and pulmonary embolism: thrombotic embolism, tumor embolism, and tumor invasion into a large vein. Circ J. 2006;70(6):744–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res. 2001;102(6):V215–24.PubMedCrossRefGoogle Scholar
  32. 32.
    Leone G, Sica S, Chiusolo P, Teofili L, De Stefano V. Blood cells diseases and thrombosis. Haematologica. 2001;86(12):1236–44.PubMedGoogle Scholar
  33. 33.
    de Gaetano G, Cerletti C, Evangelista V. Recent advances in platelet-polymorphonuclear leukocyte interaction. Haemostasis. 1999;29(1):41–9.PubMedGoogle Scholar
  34. 34.
    Kamikura Y, Wada H, Nobori T, Kobayashi T, Sase T, Nishikawa M, et al. Elevated levels of leukocyte tissue factor mRNA in patients with venous thromboembolism. Thromb Res. 2005;116(4):307–12.PubMedCrossRefGoogle Scholar
  35. 35.
    Sase T, Wada H, Yamaguchi M, Ogawa S, Kamikura Y, Nishikawa M, et al. Haemostatic abnormalities and thrombotic disorders in malignant lymphoma. Thromb Haemost. 2005;93(1):153–9.PubMedGoogle Scholar
  36. 36.
    Stein E, McMahon B, Kwaan H, Altman JK, Frankfurt O, Tallman MS. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res. 2009;22(1):153–63.Google Scholar
  37. 37.
    Lisman T, de Groot PG, Meijers JC, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood. 2005;105(3):1102–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Wang J, Weiss I, Svoboda K, Kwaan HC. Thrombogenic role of cells undergoing apoptosis. Br J Haematol. 2001;115(2):382–91.PubMedCrossRefGoogle Scholar
  39. 39.
    Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, Colon J, et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost. 2008;6(9):1517–24.PubMedCrossRefGoogle Scholar
  40. 40.
    Nijziel MR, van Oerle R, Christella M, Thomassen LG, van Pampus EC, Hamulyak K, et al. Acquired resistance to activated protein C in breast cancer patients. Br J Haematol. 2003;120(1):117–22.PubMedCrossRefGoogle Scholar
  41. 41.
    Pusterla S, Previtali S, Marziali S, Cortelazzo S, Rossi A, Barbui T, et al. Antiphospholipid antibodies in lymphoma: prevalence and clinical significance. Hematol J. 2004;5(4):341–6.PubMedCrossRefGoogle Scholar
  42. 42.
    Genvresse I, Luftner D, Spath-Schwalbe E, Buttgereit F. Prevalence and clinical significance of anticardiolipin and anti-beta2-glycoprotein-I antibodies in patients with non-Hodgkin’s lymphoma. Eur J Haematol. 2002;68(2):84–90.PubMedCrossRefGoogle Scholar
  43. 43.
    Horowitz N, Brenner B. Thrombophilia and cancer. Pathophysiol Haemost Thromb. 2008;36(3–4):131–6.PubMedGoogle Scholar
  44. 44.
    Decousus H, Moulin N, Quenet S, Bost V, Rivron-Guillot K, Laporte S, et al. Thrombophilia and risk of venous thrombosis in patients with cancer. Thromb Res. 2007;120(Suppl 2):S51–61.PubMedCrossRefGoogle Scholar
  45. 45.
    Abramson N, Costantino JP, Garber JE, Berliner N, Wickerham DL, Wolmark N. Effect of Factor V Leiden and prothrombin G20210–>A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. J Natl Cancer Inst. 2006;98(13):904–10.PubMedCrossRefGoogle Scholar
  46. 46.
    Lechner D, Weltermann A. Chemotherapy-induced thrombosis: a role for microparticles and tissue factor? Semin Thromb Hemost. 2008;34(2):199–203.PubMedCrossRefGoogle Scholar
  47. 47.
    Mandala M, Falanga A, Labianca R. Video meliora proboque sed deteriora sequor: The case of thromboprophylaxis in hospitalized cancer patients. Ann Oncol. 2010;21(5):911–3.Google Scholar
  48. 48.
    Mitchell LG, Sutor AH, Andrew M. Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment. Semin Thromb Hemost. 1995;21(4):390–401.PubMedCrossRefGoogle Scholar
  49. 49.
    Jorgensen KA, Sorensen P, Freund L. Effect of glucocorticosteroids on some coagulation tests. Acta Haematol. 1982;68(1):39–42.PubMedCrossRefGoogle Scholar
  50. 50.
    Singhal S, Mehta J. Thalidomide in cancer. Biomed Pharmacother. 2002;56(1):4–12.PubMedCrossRefGoogle Scholar
  51. 51.
    Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002;100(4):1168–71.PubMedCrossRefGoogle Scholar
  52. 52.
    Bennett CL, Schumock GT, Desai AA, Kwaan HC, Raisch DW, Newlin R, et al. Thalidomide-associated deep vein thrombosis and pulmonary embolism. Am J Med. 2002;113(7):603–6.PubMedCrossRefGoogle Scholar
  53. 53.
    Agnelli G, Verso M. Therapy Insight: venous-catheter-related thrombosis in cancer patients. Nat Clin Pract Oncol. 2006;3(4):214–22.PubMedCrossRefGoogle Scholar
  54. 54.
    Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol. 2003;21(19):3665–75.PubMedCrossRefGoogle Scholar
  55. 55.
    Monreal M, Munoz FJ, Rosa V, Romero C, Roman P, Di Micco P, et al. Upper extremity DVT in oncological patients: analysis of risk factors. Data from the RIETE registry. Exp Oncol. 2006;28(3):245–7.PubMedGoogle Scholar
  56. 56.
    Lee AY, Levine MN, Butler G, Webb C, Costantini L, Gu C, et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol. 2006;24(9):1404–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New Engl J Med. 2003;349(2):146–53.PubMedCrossRefGoogle Scholar
  58. 58.
    Mandala M, Falanga A, Piccioli A, Prandoni P, Pogliani EM, Labianca R, et al. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Cri Rev Oncol Hematol. 2006;59(3):194–204.PubMedCrossRefGoogle Scholar
  59. 59.
    Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25(34):5490–505.PubMedCrossRefGoogle Scholar
  60. 60.
    Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005;23(10):2123–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Noble SI, Nelson A, Turner C, Finlay IG. Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study. BMJ. 2006;332(7541):577–80.PubMedCrossRefGoogle Scholar
  62. 62.
    Rajkumar SV, Blood E. Lenalidomide and venous thrombosis in multiple myeloma. New Engl J Med. 2006;354(19):2079–80.PubMedCrossRefGoogle Scholar
  63. 63.
    Zangari M, Elice F, Fink L, Tricot G. Thrombosis in multiple myeloma. Expert Rev Anticancer Ther. 2007;7(3):307–15.PubMedCrossRefGoogle Scholar
  64. 64.
    Maxwell GL, Synan I, Dodge R, Carroll B, Clarke-Pearson DL. Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. Obstet Gynecol. 2001;98(6):989–95.PubMedCrossRefGoogle Scholar
  65. 65.
    Young AM, Billingham LJ, Begum G, Kerr DJ, Hughes AI, Rea DW, et al. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet. 2009;373(9663):567–74.PubMedCrossRefGoogle Scholar
  66. 66.
    Kakkar AK, Levine M, Pinedo HM, Wolff R, Wong J. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist. 2003;8(4):381–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Korte W, Greiner J. PARKAA paves the way. Thromb Haemost. 2003;90(2):163–4.PubMedGoogle Scholar
  68. 68.
    Nand S, Molokie R. Therapeutic plasmapheresis and protein A immunoadsorption in malignancy: a brief review. J Clin Apheresis. 1990;5(4):206–12.PubMedCrossRefGoogle Scholar
  69. 69.
    Zerati AE, Wolosker N, Yazbek G, Langer M, Nishinari K. Vena cava filters in cancer patients: experience with 50 patients. Clinics (Sao Paulo). 2005;60(5):361–6.PubMedCrossRefGoogle Scholar
  70. 70.
    Usoh F, Hingorani A, Ascher E, Shiferson A, Tran V, Marks N, et al. Long-term follow-up for superior vena cava filter placement. Ann Vasc Surg. 2009;23(3):350–4.PubMedCrossRefGoogle Scholar
  71. 71.
    Bodensteiner DC, Doolittle GC. Adverse haematological complications of anticancer drugs. Clinical presentation, management and avoidance. Drug Saf. 1993;8(3):213–24.PubMedCrossRefGoogle Scholar
  72. 72.
    Avvisati G, Tirindelli MC, Annibali O. Thrombocytopenia and hemorrhagic risk in cancer patients. Crit Rev Oncol Hematol. 2003;48(Suppl):S13–6.PubMedCrossRefGoogle Scholar
  73. 73.
    Webert K, Cook RJ, Sigouin CS, Rebulla P, Heddle NM. The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica. 2006;91(11):1530–7.PubMedGoogle Scholar
  74. 74.
    Wandt H, Frank M, Ehninger G, Schneider C, Brack N, Daoud A, et al. Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood. 1998;91(10):3601–6.PubMedGoogle Scholar
  75. 75.
    Le Maitre A, Ding K, Shepherd FA, Leighl N, Arnold A, Seymour L. Anticoagulation and bleeding: a pooled analysis of lung cancer trials of the NCIC Clinical Trials Group. J Thorac Oncol. 2009;4(5):586–94.PubMedCrossRefGoogle Scholar
  76. 76.
    Elting LS, Cantor SB, Martin CG, Hamblin L, Kurtin D, Rivera E, et al. Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer. 2003;97(6):1541–50.PubMedCrossRefGoogle Scholar
  77. 77.
    Deichmann M, Helmke B, Bock M, Jackel A, Waldmann V, Flechtenmacher C, et al. Massive lethal cerebral bleeding in a patient with melanoma without intracranial metastasis. Clin Oncol (R Coll Radiol). 1998;10(4):272–3.CrossRefGoogle Scholar
  78. 78.
    Koscielny J, von Tempelhoff GF, Ziemer S, Radtke H, Schmutzler M, Sinha P, et al. A practical concept for preoperative management of patients with impaired primary hemostasis. Clin Appl Thromb Hemost. 2004;10(2):155–66.PubMedCrossRefGoogle Scholar
  79. 79.
    Lehmann FS, Beglinger C. Impact of COX-2 inhibitors in common clinical practice a gastroenterologist’s perspective. Curr Top Med Chem. 2005;5(5):449–64.PubMedCrossRefGoogle Scholar
  80. 80.
    Lee Y, Rodriguez C, Dionne RA. The role of COX-2 in acute pain and the use of selective COX-2 inhibitors for acute pain relief. Curr Pharm Des. 2005;11(14):1737–55.PubMedCrossRefGoogle Scholar
  81. 81.
    Salinas G, Rangasetty UC, Uretsky BF, Birnbaum Y. The cycloxygenase 2 (COX-2) story: it’s time to explain, not inflame. J Cardiovasc Pharmacol Ther. 2007;12(2):98–111.PubMedCrossRefGoogle Scholar
  82. 82.
    Spectre G, Libster D, Grisariu S, Da’as N, Yehuda DB, Gimmon Z, et al. Bleeding, obstruction, and perforation in a series of patients with aggressive gastric lymphoma treated with primary chemotherapy. Ann Surg Oncol. 2006;13(11):1372–8.PubMedCrossRefGoogle Scholar
  83. 83.
    Desai SP, Ben-Josef E, Normolle DP, Francis IR, Greenson JK, Simeone DM, et al. Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer. J Clin Oncol. 2007;25(29):4587–92.PubMedCrossRefGoogle Scholar
  84. 84.
    Rocha E, Paramo JA, Montes R, Panizo C. Acute generalized, widespread bleeding. Diagnosis and management. Haematologica. 1998;83(11):1024–37.PubMedGoogle Scholar
  85. 85.
    Okajima K, Sakamoto Y, Uchiba M. Heterogeneity in the incidence and clinical manifestations of disseminated intravascular coagulation: a study of 204 cases. Am J Hematol. 2000;65(3):215–22.PubMedCrossRefGoogle Scholar
  86. 86.
    Tallman MS, Lefebvre P, Baine RM, Shoji M, Cohen I, Green D, et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost. 2004;2(8):1341–50.PubMedCrossRefGoogle Scholar
  87. 87.
    Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. New Engl J Med. 1999;340(13):994–1004.PubMedCrossRefGoogle Scholar
  88. 88.
    Kwaan HC, Wang J, Weiss I. Expression of receptors for plasminogen activators on endothelial cell surface depends on their origin. J Thromb Haemost. 2004;2(2):306–12.PubMedCrossRefGoogle Scholar
  89. 89.
    Sallah S, Wan JY. Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients. Cancer. 2001;91(6):1067–74.PubMedCrossRefGoogle Scholar
  90. 90.
    Wettstein P, Haeberli A, Stutz M, Rohner M, Corbetta C, Gabi K, et al. Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding. Anesth Analg. 2004;99(5):1564–9; table of contents.Google Scholar
  91. 91.
    Korte W, Gabi K, Rohner M, Gahler A, Szadkowski C, Schnider TW, et al. Preoperative fibrin monomer measurement allows risk stratification for high intraoperative blood loss in elective surgery. Thromb Haemost. 2005;94(1):211–5.PubMedGoogle Scholar
  92. 92.
    Korte WC, Szadkowski C, Gahler A, Gabi K, Kownacki E, Eder M, et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology. 2009;110(2):239–45.PubMedGoogle Scholar
  93. 93.
    Kasturi J, Saraya AK. Platelet functions in dysproteinaemia. Acta Haematol. 1978;59(2):104–13.PubMedCrossRefGoogle Scholar
  94. 94.
    Colwell NS, Tollefsen DM, Blinder MA. Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder. Br J Haematol. 1997;97(1):219–26.PubMedCrossRefGoogle Scholar

Copyright information

© Society for Imaging Informatics in Medicine 2010

Authors and Affiliations

  1. 1.Institute for Clinical Chemistry and HematologyKantonsspital St. GallenSt. GallenSwitzerland
  2. 2.University of BernBernSwitzerland

Personalised recommendations